Tratamiento con Nifurtimox de la infección chagásica crónica en niños

Abstract

En el Artículo de Investigación «Integrones y cassettes genéticos de resistencia a antimicrobianos en cepas de Shigella flexneri» de Jeannette Muñoz et al (Rev Méd Chile 2003; 131: 727-33), la Figura 3 no debió publicarse, por solicitud oportuna de los autores. Su inclusión fue un error involuntario de los Editores.

Present situation and new strategies for Chagas disease chemotherapy: a proposal

“…Today, this medication is produced and used predominantly in Central America. Nifurtimox is the most active of the 5-nitrofurfuridenes tested experimentally by Bock et al in 1969 and clinically by several other researchers (Bocca-Tourres 1969, Cançado et al 1969, 1976, Rubio & Donoso 1969, Schenone et al 1969, 1972, 1981, Rassi & Ferreira 1971, Prata et al 1975, Ferreira 1990, Rassi & Luquetti 1992, Coura 1996, Coura et al 1997. All research shows the best results are obtained when treatment is started during the acute phase; results are highly variable for patients in the chronic phase.…”

Experiencia terapéutica en un centro para la enfermedad de Chagas

“…La tolerancia suele ser buena en niños 21 . En adultos es esperable la aparición de reacciones adversas en aproximadamente 30%, relacionadas con su mecanismo de acción 5,8,22 .…”

Vertical transmission of Trypanosoma cruzi in the Province of Choapa, IV Region, Chile: Preliminary Report (2005-2008)

“…Some rural areas of the IV Region are still considered as zones of high Chagas endemism due to the high indices of domestic infestation (66.9%) (Correa et al, 1984), and infection of humans (41.2%) (Apt and Reyes, 1986), animals (41.2%) (Rios et al, 1986) and triatomines (37.8%) (Apt and Reyes, 1986) reported in past decades. Although in 1999 Chile was certified to have interrupted the mechanisms of vector transmission of Trypanosoma cruzi by Triatoma infestans and by blood bank transfusions, vertical transmission is still a public health problem (Schenone et al, 2003).…”